Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/05/2026 08:01 PDT] NKTR Expected to Trade Up After Bullish Patterns Develop
• [05/22/2026 07:15 PDT] NKTR Expected to Trade Up After Bullish Patterns Develop
• [04/22/2026 09:51 PDT] Nektar Therapeutics (NASDAQ:NKTR), Up By 100% ($74.72) From $74.72 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/22/2026 09:51 PDT] Nektar Therapeutics (NASDAQ:NKTR), Up By 100% ($76.99) From $76.99 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/22/2026 09:51 PDT] Nektar Therapeutics (NASDAQ:NKTR), Up By 100% ($75.71) From $75.71 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions